報價延遲最少15分鐘:2025/11/04 07:40 EST
盤前時段
|
||||
|
0.7344 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.73
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.30/-1.08
|
|
企業價值
129.04M
|
| 資產負債 |
|
每股賬面淨值
0.87
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/11/04 07:40 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. |
